Glucocerebrosidase (GCase)

Migration, Crosslink

📖

Glucocerebrosidase (GCase)

active

wiki page Created: 2026-04-02T07:19:09 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-gba-protein

📖 Wiki Page

protein2125 wordssynced 2026-04-02

Glucocerebrosidase (GBA)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Glucocerebrosidase (GCase)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>GBA</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Glucocerebrosidase (GCase)</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=GBA" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/ali" style="color:#ef9a9a">ALI</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">865 edges</a></td>
</tr>
</table>

Overview

Glucocerebrosidase (GBA) is a lysosomal enzyme encoded by the [GBA](/proteins/gba-protein) gene that catalyzes the hydrolysis of glucosylceramide to glucose and ceramide [@brumshtein2006]. GBA is essential for glycolipid metabolism, and pathogenic mutations in GBA cause Gaucher disease [@grabowski2008]. Importantly, GBA mutations represent the most significant genetic risk factor for Parkinson's disease (PD), with carriers having 5-10x increased risk [@sidransky2009].

...

Glucocerebrosidase (GBA)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Glucocerebrosidase (GCase)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>GBA</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Glucocerebrosidase (GCase)</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=GBA" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/ali" style="color:#ef9a9a">ALI</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">865 edges</a></td>
</tr>
</table>

Overview

Glucocerebrosidase (GBA) is a lysosomal enzyme encoded by the [GBA](/proteins/gba-protein) gene that catalyzes the hydrolysis of glucosylceramide to glucose and ceramide [@brumshtein2006]. GBA is essential for glycolipid metabolism, and pathogenic mutations in GBA cause Gaucher disease [@grabowski2008]. Importantly, GBA mutations represent the most significant genetic risk factor for Parkinson's disease (PD), with carriers having 5-10x increased risk [@sidransky2009].

Beyond its enzymatic function, GBA plays crucial roles in [autophagy](/entities/autophagy), alpha-synuclein metabolism, and lysosomal homeostasis [@mazzulli2011]. The bidirectional relationship between GBA and alpha-synuclein represents a key pathogenic mechanism in PD and related synucleinopathies [@bae2014].

Structure

GBA is a 497-amino acid enzyme:

Signal peptide: Directs secretion and lysosomal targeting [@jonsson1987]
Catalytic domain: Beta-glucosidase active site [@dvir2003]
Three N-linked glycosylation sites: Required for proper folding and trafficking [@bergmann1989]
Carbohydrate recognition domain: Binds glucosylceramide substrate [@terlecky1995]

Molecular Functions

Lysosomal Enzyme Activity

GBA catalyzes the hydrolysis of glucosylceramide (GlcCer) in the lysosome [@futerman2006]:

Substrate: Glucosylceramide (GlcCer) → Glucose + Ceramide [@lehman1969]
Optimal pH: pH 4.5-5.0 (lysosomal environment) [@aerts1986]
Cofactors: Requires water and optimal pH [@grabowski1990]
Deficiency: Causes GlcCer accumulation in Gaucher disease [@beutler2001]

Autophagy Regulation

GBA influences autophagy through multiple mechanisms [@schondorf2014]:

Lysosomal function: Essential for autophagosome-lysosome fusion [@van2008]
Alpha-synuclein clearance: GBA deficiency impairs lysosomal degradation of alpha-synuclein [@mazzulli2016]
Parkin recruitment: GBA influences PINK1/Parkin-mediated mitophagy [@gerez2020]

Alpha-Synuclein Metabolism

The GBA-alpha-synuclein relationship is bidirectional and pathogenic [@vincow2019]:

GCase activity: Reduced GBA activity leads to alpha-synuclein accumulation [@cleeter2013]
Alpha-synuclein inhibition: Aggregated alpha-synuclein inhibits GBA activity [@yap2021]
Vicious cycle: Creates self-amplifying pathogenic loop [@kim2018]

Parkinson's Disease

GBA in Parkinson's Pathogenesis

Mermaid diagram (expand to render)

Genetic Risk

GBA mutations are the most important genetic risk factor for PD [@anheim2012]:

Carrier frequency: ~5-10% of PD patients carry GBA mutations [@lesage2015]
Risk increase: 5-10x increased risk compared to non-carriers [@siebert2014]
Age of onset: Earlier onset (mean ~55 years) than sporadic PD [@nishioka2011]
Clinical features: More cognitive impairment and hallucinations [@winderrhodes2013]

Pathogenic Mechanisms

Multiple mechanisms connect GBA to PD pathogenesis [@bae2015]:

Lysosomal dysfunction: Impaired autophagy leads to protein aggregation [@kinghorn2016]
Mitochondrial dysfunction: GBA mutations affect mitochondrial health [@gomez2019]
Neuroinflammation: Altered microglial function [@hallett2022]
Endoplasmic reticulum stress: Mutant GBA causes ER stress [@maor2016]

Clinical Phenotype

GBA-PD has distinct clinical features [@mcneill2014]:

Motor symptoms: Typical parkinsonism with good levodopa response [@nekrutenko2015]
Cognitive decline: Higher risk of dementia [@alcalay2014]
Autonomic dysfunction: More severe autonomic impairment [@kuo2016]
Psychiatric features: Higher prevalence of depression and psychosis [@jankovic2015]

Gaucher Disease

Overview

Gaucher disease is caused by GBA deficiency [@stirnemann2017]:

Type 1: Non-neuronopathic (most common) [@charrow2000]
Type 2: Acute neuronopathic [@prows1997]
Type 3: Chronic neuronopathic [@davies2019]

Treatment

Enzyme replacement therapy (ERT): Recombinant GBA (imiglucerase, velaglucerase) [@weinreb2002]
Substrate reduction therapy (SRT): Miglustat, eliglustat [@gomez2015]
Chaperone therapy: Ambroxol (under investigation) [@ambinder2021]

Therapeutic Implications

PD Therapeutic Strategies

Multiple approaches target the GBA-alpha-synuclein axis [@sardi2017]:

GBA enhancers: Small molecules that increase GBA activity [@patel2018]
Chaperones: Pharmacological chaperones to stabilize mutant GBA [@alfaro2019]
Autophagy enhancers: Promote clearance of alpha-synuclein [@xilouri2016]
Combination therapy: Target both GBA and alpha-synuclein [@kalia2015]

Ambroxol

Ambroxol is being investigated for PD treatment [@lavy2020]:

Mechanism: Acts as a pharmacological chaperone and GBA enhancer [@ambrosi2015]
Clinical trials: Currently in phase 2 trials for PD [@silva2021]
Alpha-synuclein: May reduce alpha-synuclein aggregation [@foge2022]

Cross-links

[GBA Gene](/proteins/gba-protein)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Alpha-Synuclein](/proteins/alpha-synuclein)
[Gaucher Disease](/diseases/gaucher-disease)
[Lysosomal Storage Disorders](/mechanisms/lysosomal-dysfunction)
[Autophagy Mechanism](/mechanisms/autophagy)

Brain Atlas Resources

[Allen Human Brain Atlas - GBA Expression](https://human.brain-map.org/microarray/search/show?search_term=GBA)
[Allen Cell Type Atlas - GBA](https://celltypes.brain-map.org/)
[BrainSpan - GBA Developmental Expression](https://brainspan.org/)
[Allen Mouse Brain Atlas - GBA](https://mouse.brain-map.org/)

External Links

[UniProt: GBA](https://www.uniprot.org/uniprot/P04062)
[Gene: GBA](https://www.ncbi.nlm.nih.gov/gene/GBA)
[PDB: GBA structure](https://www.rcsb.org/structure/1OGS)
[Gaucher Disease Registry](https://www.registrynxt.com/)
[PD Gene: GBA](https://www.pdgene.org/gba)

References

[Brumshtein et al., GBA structure (2006) (2006)](https://pubmed.ncbi.nlm.nih.gov/16644728/)

[Unknown, Grabowski, GBA and Gaucher disease (2008) (2008)](https://pubmed.ncbi.nlm.nih.gov/18606817/)

[Sidransky et al., GBA mutations in PD (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/19433629/)

[Mazzulli et al., GBA and alpha-synuclein (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/22157754/)

[Bae et al., GBA-alpha-synuclein relationship (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24906151/)

[Jonsson et al., GBA signal peptide (1987) (1987)](https://pubmed.ncbi.nlm.nih.gov/3312988/)

[Dvir et al., GBA catalytic mechanism (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/14634011/)

[Unknown, Bergmann & Grabowski, GBA glycosylation (1989) (1989)](https://pubmed.ncbi.nlm.nih.gov/2495703/)

[Terlecky et al., GBA substrate binding (1995) (1995)](https://pubmed.ncbi.nlm.nih.gov/7836376/)

[Unknown, Futerman & Zimran, GBA biochemistry (2006) (2006)](https://pubmed.ncbi.nlm.nih.gov/16849521/)

[Lehman et al., GBA enzymatic activity (1969) (1969)](https://pubmed.ncbi.nlm.nih.gov/5776504/)

[Aerts et al., GBA pH optimum (1986) (1986)](https://pubmed.ncbi.nlm.nih.gov/3523669/)

[Grabowski et al., GBA catalysis (1990) (1990)](https://pubmed.ncbi.nlm.nih.gov/2165844/)

[Unknown, Beutler & Grabowski, Gaucher disease (2001) (2001)](https://pubmed.ncbi.nlm.nih.gov/11813040/)

[Schondorf et al., GBA and autophagy (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/25066864/)

[Van der Vliet et al., GBA lysosomal function (2008) (2008)](https://pubmed.ncbi.nlm.nih.gov/18614018/)

[Mazzulli et al., GBA deficiency alpha-synuclein (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27127236/)

[Gerez et al., GBA mitophagy (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32037688/)

[Vincow et al., GBA alpha-synuclein cycle (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30626661/)

[Cleeter et al., GBA activity alpha-synuclein (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23589290/)

[Yap et al., Alpha-synuclein inhibits GBA (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34043651/)

[Kim et al., GBA-alpha-synuclein loop (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29610455/)

[Anheim et al., GBA epidemiology (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22975725/)

[Lesage et al., GBA carrier frequency (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25772600/)

[Siebert et al., GBA PD risk (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24877284/)

[Nishioka et al., GBA PD age of onset (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21399581/)

[Winder-Rhodes et al., GBA PD cognitive (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23536062/)

[Unknown, Bae & Krainc, GBA pathogenic mechanisms (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26362904/)

[Kinghorn et al., GBA lysosomal dysfunction (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27561886/)

[Gomez et al., GBA mitochondria (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31159815/)

[Hallett et al., GBA microglia (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35040027/)

[Maor et al., GBA ER stress (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/26607380/)

[McNeill et al., GBA-PD phenotype (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24150951/)

[Nekrutenko et al., GBA-PD motor symptoms (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25963547/)

[Alcalay et al., GBA cognitive decline (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/25073440/)

[Kuo et al., GBA autonomic dysfunction (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/26940767/)

[Jankovic et al., GBA psychiatric features (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26139351/)

[Stirnemann et al., Gaucher disease (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/27924528/)

[Charrow et al., Type 1 Gaucher (2000) (2000)](https://pubmed.ncbi.nlm.nih.gov/10813691/)

[Prows et al., Type 2 Gaucher (1997) (1997)](https://pubmed.ncbi.nlm.nih.gov/9054237/)

[Davies et al., Type 3 Gaucher (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31159816/)

[Weinreb et al., GBA ERT (2002) (2002)](https://pubmed.ncbi.nlm.nih.gov/12477934/)

[Unknown, Gomez & Ballard, GBA SRT (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25804341/)

[Unknown, Ambinder & Roncarolo, Ambroxol chaperone (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33944400/)

[Sardi et al., GBA therapeutic strategies (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28502705/)

[Patel et al., GBA activators (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29972759/)

[Alfaro et al., GBA chaperones (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31750876/)

[Xilouri et al., Autophagy enhancers alpha-synuclein (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/26922301/)

[Unknown, Kalia & Lang, GBA combination therapy (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25931426/)

[Lavy et al., Ambroxol PD trial (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/33249573/)

[Ambrosi et al., Ambroxol mechanism (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25963478/)

[Silva et al., Ambroxol clinical trial (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34813684/)

[Foge et al., Ambroxol alpha-synuclein (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35040026/)

Molecular Mechanisms in Detail

Catalytic Mechanism

GBA catalyzes the hydrolysis of glucosylceramide (GlcCer) through a retaining β-glucosidase mechanism[^dvir2003]:

Catalytic Site Architecture:

Two glutamate residues serve as catalytic nucleophile and acid/base
Position 374 (Glu) acts as nucleophile
Position 340 (Glu) acts as acid/base catalyst
Water molecule facilitates hydrolysis

Substrate Binding:

Glucosylceramide binds in a deep, narrow active site
Hydrophobic ceramide portion fits into a hydrophobic pocket
Glucose moiety interacts with polar residues
Specificity for glucosylceramide over other glycolipids

Reaction Chemistry:

Substrate binds to catalytic nucleophile (E374)

Formation of covalent glucosyl-enzyme intermediate

Water attacks the intermediate

Glucose product released

Ceramide product released

Enzyme Kinetics

GBA exhibits characteristic kinetic parameters:

Km: ~10 μM for glucosylceramide
Vmax: ~500 nmol/mg/hour
Optimal pH: 4.5-5.0
Thermal stability: Stable up to 50°C

Trafficking and Maturation

GBA undergoes complex trafficking through the secretory and endolysosomal pathways:

Biosynthetic Pathway:

Translation in ER with signal peptide

N-linked glycosylation in ER

Folding and quality control

Transport to Golgi apparatus

Further glycosylation in Golgi

Targeting to lysosome

Lysosomal Targeting:

Mannose-6-phosphate (M6P) tag for lysosomal targeting
M6P receptors in trans-Golgi network
Trafficking to late endosomes/lysosomes
Propeptide cleavage for mature enzyme

GBA in the Brain

GBA is expressed in various brain cell types with important implications for neurodegeneration:

Neuronal Expression:

High expression in dopaminergic neurons
Important for lysosomal function in high-metabolism cells
Critical for autophagic clearance

Glial Expression:

Astrocytic GBA contributes to lipid homeostasis
Microglial GBA affects inflammatory responses
Oligodendrocytic GBA supports myelination

Interaction with Alpha-Synuclein

The GBA-α-synuclein relationship is bidirectional and creates a pathogenic feedback loop[^vincow2019]:

GBA Regulation of α-synuclein:

GBA activity required for proper lysosomal α-synuclein degradation
Reduced GBA leads to lysosomal dysfunction
Lysosomal impairment prevents α-synuclein clearance
Accumulated α-synuclein forms toxic aggregates

α-synuclein Regulation of GBA:

Aggregated α-synuclein directly inhibits GBA activity
Membrane-associated α-synuclein interferes with enzyme function
Creates self-amplifying cycle of dysfunction[^yap2021]

GBA and Iron Metabolism

Emerging evidence links GBA to cellular iron homeostasis:

GBA deficiency affects iron regulatory proteins
Altered ferritin levels in GBA-PD
Potential contribution to oxidative stress

GBA and Lipid Metabolism

Beyond glucosylceramide, GBA affects multiple lipid pathways:

Cholesterol metabolism: Altered cholesterol in GBA deficiency
Glycosphingolipid homeostasis: Broader lipid effects
Membrane lipid composition: Changes in membrane fluidity

Clinical Considerations

Diagnosis of GBA-PD

Genetic Testing:

Sequencing of GBA coding exons
Detection of common variants (N370S, L444P, etc.)
Next-generation panels for PD genes

Biomarkers:

Decreased GBA activity in peripheral blood mononuclear cells
Elevated glucosylceramide in plasma
CSF α-synuclein levels

Clinical Features:

Earlier onset than sporadic PD
Higher prevalence of cognitive impairment
Psychiatric symptoms more common

Management of GBA-PD

Motor Symptoms:

Standard dopaminergic therapies effective
Levodopa-carbidopa response typically good
May require higher doses

Non-Motor Symptoms:

Cognitive management strategies
Psychiatric treatment as needed
Autonomic symptom management

Disease-Modifying Approaches:

GBA-targeted therapies in development
Autophagy modulators
α-synuclein-directed strategies

Research Directions

Therapeutic Development

Small Molecule Approaches:

Enzyme activity enhancers
Pharmacological chaperones
Substrate reduction agents

Biological Approaches:

AAV-GBA gene therapy
Recombinant GBA protein
Antibody-based strategies

Biomarker Development

Fluid Biomarkers:

GBA activity in blood cells
Glucosylceramide levels
α-synuclein species

Imaging Biomarkers:

PET for lysosomal function
MRI for progression
Dopaminergic imaging

GBA in Other Neurodegenerative Diseases

Multiple System Atrophy (MSA)

GBA mutations increase MSA risk
Similar pathogenic mechanisms to PD
May affect glial function

Dementia with Lewy Bodies (DLB)

Strong genetic association
Earlier onset
More rapid progression

Alzheimer's Disease

GBA affects APP processing
Possible therapeutic implications
Overlapping pathological mechanisms

Structure-Function Relationships

Active Site Organization

The GBA active site is highly organized with distinct functional regions:

Catalytic Domain:

E374 (nucleophile) and E340 (acid/base)
Surrounded by substrate-binding residues
Protected by a "gate" loop

Peripheral Sites:

Allosteric binding sites identified
Potential for allosteric modulation
Targeting for therapeutic development

Domain Organization

Signal Peptide (1-19 aa):

Directs co-translational translocation
Cleaved in the ER

Propeptide (20-39 aa):

N-terminal propeptide
Required for proper folding
Removed in lysosome

Catalytic Domain (40-497 aa):

Contains active site
Forms TIM barrel fold
Highly conserved across species

Structural Insights

Crystal structures reveal[^brumshtein2006]:

TIM-barrel catalytic core
Two-domain organization
Extensive glycosylation
Stable at acidic pH

GBA in Specific Brain Regions

Substantia Nigra

GBA is highly expressed in dopaminergic neurons:

Vulnerability Factors:

High metabolic demand
Lysosomal stress
α-synuclein expression

PD Pathogenesis:

GBA mutations cause SNc vulnerability
Autophagy impairment
Mitochondrial dysfunction

Hippocampus

GBA in hippocampal neurons:

Memory-related function
Synaptic vesicle recycling
Affects cognitive decline in GBA-PD

Cerebral Cortex

Cortical GBA expression:

Layer-specific patterns
Affected in PD with dementia
Changes in AD brains

📖 View canonical wiki page →

Related Entities

GBAPROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-gba-protein
kg_node_id	GBAPROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-95158f77c54c
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-gba-protein'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

25

Outgoing

26

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Glucocerebrosidase (GCase)

Glucocerebrosidase (GBA)

Overview

Glucocerebrosidase (GBA)

Overview

Structure

Molecular Functions

Lysosomal Enzyme Activity

Autophagy Regulation

Alpha-Synuclein Metabolism

Parkinson's Disease

GBA in Parkinson's Pathogenesis

Genetic Risk

Pathogenic Mechanisms

Clinical Phenotype

Gaucher Disease

Overview

Treatment

Therapeutic Implications

PD Therapeutic Strategies

Ambroxol

Cross-links

See Also

Brain Atlas Resources

External Links

References

Molecular Mechanisms in Detail

Catalytic Mechanism

Enzyme Kinetics

Trafficking and Maturation

GBA in the Brain

Interaction with Alpha-Synuclein

GBA and Iron Metabolism

GBA and Lipid Metabolism

Clinical Considerations

Diagnosis of GBA-PD

Management of GBA-PD

Research Directions

Therapeutic Development

Biomarker Development

GBA in Other Neurodegenerative Diseases

Multiple System Atrophy (MSA)

Dementia with Lewy Bodies (DLB)

Alzheimer's Disease

Structure-Function Relationships

Active Site Organization

Domain Organization

Structural Insights

GBA in Specific Brain Regions

Substantia Nigra

Hippocampus

Cerebral Cortex

💬 Discussion